LAS VEGAS, Oct. 18, 2017 -- The global Diabetic Retinopathy Market is projected to be around $2.6 billion by 2025. This growth can be attributed to increase in prevalence of diabetes, increase in demand for early screening techniques and increase awareness about disease and available treatments among patients. Increasing incidence of diabetes caused blindness will further enhance the growth of market during forecast period. As per International Diabetes Federation (IDF) 415 million people worldwide suffered from diabetes and diabetes related complications as of 2015 and this number is expected to reach 642 million by 2040. Diabetic retinopathy is characterized by neovascularization of retina, blurred vision and moderate to severe eye pain. This further leads to retinal detachment and complete loss of vision. Such high complications will lead to increase in demand for methods to treat diabetes retinopathy which will drive the market during forecast period However, dearth of skilled professionals and poor insurance facilities are restraining the market growth.
Major Key Player
Bayer Healthcare
Novartis AG
Actavis PLC
ThromboGenics
irnaomics Incorporation
Genentech
Glycadia Pharmaceuticals
Regeneron Pharmaceuticals Inc.
Alimera Sciences
Ampio Pharmaceuticals.
Get complete access to Reports: http://www.crystalmarketresearch.com/report/diabetic-retinopathy-market
Diabetic Retinopathy Market is segmented as follows –
By Type:
- Proliferative Diabetic Retinopathy
- Diabetic Macular Edema
By Management:
- Anti VEGF Drugs
- Steroid Implants
- Laser Surgeries
- Vitrectomy
By Region:
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- United Arab Emirates
Get Sample of this Report @ http://www.crystalmarketresearch.com/report-sample/HC0622
Table of Contents
1. Introduction
2. Executive Summary
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Share Analysis
3.3. Market Dynamics
3.3.1. Drivers
3.3.1.1. High Prevalence of Diabetes
3.3.1.2. Rise in Demand for Early Detection Techniques
3.3.1.3. Increased Awareness about Diabetes
3.3.2. Restraints
3.3.2.1. Dearth of Skilled Professionals
3.3.2.2. Poor Insurance Facilities
3.3.3. Opportunities
3.3.3.1. Emerging Market to Offer Lucrative Growth Opportunities
3.4. Industry Trends
4. Diabetic Retinopathy Market, By Product
5. Diabetic Retinopathy Market, By Application
6. Diabetic Retinopathy Market, By Region
7. Company Profiles
Buy Report @ http://www.crystalmarketresearch.com/checkout/22
About Us:
Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.
Contact Us:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: [email protected]
Website: www.crystalmarketresearch.com


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 



